PCSK9-targeting lipid-lowering therapies and similar agents can produce reductions in low-density lipoprotein (LDL) cholesterol on the order of approximately 50â60% in treated patients.
high
statistical
Typical magnitude of LDL cholesterol reduction achievable with PCSK9-targeting therapies